Department of Pediatrics (Division of Pediatric Hematology and Oncology)

Experimental Therapeutics Cancer Center Program

High Risk Leukemia and Lymphoma Program, Primary Children’s Hospital (Medical Director)

Member, Hematologic Malignancies DOT

Data and Safety Monitoring Committee (Chair)

Medical Director, Research Compliance Office

bronner group banner



Refining prognosis in BCR-ABL1-positive ALL. 
Raetz E and Carroll W. 
Blood. 2014 Mar 13;123(11):1626-7.

The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL.
J Pediatr Hematol Oncol. 2014; 36(6):413-8.  PMID:  24942923.
adobe Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL.  
Pediatr Blood Cancer. 2014;61(10):1779-85. 
adobe Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
Dandekar S, Romanos-Sirakis E, Pais F, Bhatla T, Jones C, Bourgeois W, Hunger SP, Raetz EA, Hermiston ML, Dasgupta R, Morrison DJ, Carroll WL.
Br J Haematol. 2014 Jul 4. doi: 10.1111/bjh.13011. [Epub ahead of print]